Core Points - Assertio Holdings, Inc. will present new data for SYMPAZAN (clobazam) Oral Film at the 150th Annual Meeting of the American Neurological Association (ANA2025) from September 13-16, 2025 [1][2] - The poster presentation will focus on a real-world evidence study of patients with Lennox-Gastaut Syndrome taking clobazam Oral Soluble Film, detailing demographics, medications, and comorbidities [2][9] - SYMPAZAN is the first and only FDA-approved oral film formulation of clobazam for the adjunctive treatment of seizures associated with Lennox-Gastaut syndrome in patients aged two years and older [6][9] Company Overview - Assertio is a pharmaceutical company with comprehensive commercial capabilities, focusing on differentiated products in oncology, neurology, and pain management [4] - The company aims to address patients' needs through its marketed products [4] Product Information - SYMPAZAN is available in berry flavor and offered in 5 mg, 10 mg, and 20 mg dosages, consistent with other clobazam formulations [6] - The product is indicated for the adjunctive treatment of seizures associated with Lennox-Gastaut Syndrome in patients aged two years and older [7] Disease Context - Lennox-Gastaut Syndrome (LGS) is a severe epilepsy syndrome affecting approximately 50,000 people in the United States, typically diagnosed between ages three and five [5] - Managing LGS is challenging due to treatment-resistant seizures and the need for individualized approaches [5]